| 温亮 曹建 谢燚 杨庆辉 陈延军.替格瑞洛在急性冠脉综合征患者经皮冠状动脉介入治疗术后的应用价值[J].,2016,16(30):5861-5863 |
| 替格瑞洛在急性冠脉综合征患者经皮冠状动脉介入治疗术后的应用价值 |
| Clinical Value of Ticagrelor in Patients with Acute Coronary Syndrome treated by Percutaneous Coronary Intervention* |
| |
| DOI： |
| 中文关键词: 替格瑞洛 急性冠脉综合征 经皮冠状动脉介入治疗 |
| 英文关键词: Ticagrelor Acute coronary syndrome Percutaneous coronary intervention |
| 基金项目:国家自然科学基金项目(81100070) |
|
| 摘要点击次数: 913 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：评价替格瑞洛在急性冠脉综合征(acute coronary syndrome，ACS)患者经皮冠状动脉介入治疗(percutaneous coronary
intervention，PCI)术后的应用价值。方法：将我院收治的565 例成功行PCI 的急性冠脉综合征(acute coronary syndrome，ACS)患者
随机分为2 组：氯吡格雷组253 例，术后口服氯吡格雷75 mg、QD；替格瑞洛组312 例，术后口服替格瑞洛首剂180 mg，维持量90
mg、BID。两组患者术后常规口服阿司匹林100 mg、QD。研究主要终点为主要不良心血管事件(major adverse cardiovascular events，
MACE)，包括全因死亡、靶血管血运重建和脑梗塞；次要终点为TIMI主要出血(定义为血红蛋白下降>50 g/L 或颅内出血有关的
临床显著出血事件)。结果：565例患者平均随访12 个月，替格瑞洛组MACE 发生率低于氯吡格雷组(3.8%vs. 8.7%，P＜0.05)，两
组TIMI主要出血事件发生率比较，差异无统计学意义(2.9%vs. 3.2%，P>0.05)。结论：替格瑞洛能明显减少PCI术后主要不良心血
管事件，并不增加主要出血。 |
| 英文摘要: |
| Objective:To evaluate the clinical value of ticagrelor in patients with acute coronary syndrome (ACS) treated by
percutaneous coronary intervention (PCI).Methods:A total of 565 cases of ACS patients successfully treated by PCI were randomly
divided into 2 groups. Clopidogrel group (n=253) received clopidogrel 75 mg daily. Ticagrelor group received ticagrelor 180 mg loading
dose and 90 mg twice daily thereafter. Both groups received asprin 100 mg daily conventionally. The primary end points were defined as
major adverse cardiovascular events (MACE), namely a composite of death from any cause, target vessel revascularization (TVR), or
ischemic stroke. Secondary end points were major bleeding events classified by TIMI.Results:All the 565 patients were followed for an
average of 12 months and the clinical outcomes were analyzed at 12 months after PCI. The morbidity rates of MACE in Ticagrelor group
was lower than that of the Clopidogrel group at 12 months (3.8%vs. 8.7%, P<0.05). No significant difference was found in the rates of
major bleeding between the two groups (2.9%vs. 3.2%, P>0.05).Conclusion:Ticagrelor therapy significantly reduced the rate of MACE
without an increase of major bleeding after PCI. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
